Adhera Therapeutics Inc (ATRX)

[Jose Chavez]

$ATRX Adhera believes that leveraging decades of safety data and previous work conducted by Melior Discovery (“Melior”), an in vivo pharmacology-focused biopharmaceutical company and parent company of Melior Pharma 2, will qualify advancing MLR-1019 directly into a Phase 2a clinical trial for PD. To the best of either companies’ knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.) and non-movement (e.g., sleep disorders, cognitive deficits, etc.) symptoms of PD.